Measurement of free light chains with assays based on monoclonal antibodies Te Velthuis, Henk; Drayson, Mark; Campbell, John
|
|
- Debra Wilkerson
- 6 years ago
- Views:
Transcription
1 Measurement of free light chains with assays based on monoclonal antibodies Te Velthuis, Henk; Drayson, Mark; Campbell, John DOI:.55/cclm License: None: All rights reserved Document Version Peer reviewed version Citation for published version (Harvard): Te Velthuis, H, Drayson, M & Campbell, JP 26, 'Measurement of free light chains with assays based on monoclonal antibodies' Clinical Chemistry and Laboratory Medicine. DOI:.55/cclm Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked for eligibility: 8/4/26 General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. Users may freely distribute the URL that is used to identify this publication. Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. User may use extracts from the document in line with the concept of fair dealing under the Copyright, Designs and Patents Act 988 (?) Users may not further distribute the material nor use it for the purposes of commercial gain. Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document. When citing, please reference the published version. Take down policy While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive. If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate. Download date: 9. May. 28
2 Clin Chem Lab Med 26; aop Mini Review Henk te Velthuis, Mark Drayson and John P. Campbell* Measurement of free light chains with assays based on monoclonal antibodies DOI.55/cclm Received October 2, 25; accepted February 8, 26 Abstract: Recently, serum free light chain (FLC) assays incorporating anti-kappa (κ) and anti-lambda (λ) FLC monoclonal antibodies have become available: N Latex FLC assay (Siemens) and Seralite (Abingdon Health). The purpose of this review is to provide an overview of these two new monoclonal antibody-based methods. In doing so, the review will outline the performance characteristics of each method, including a summary of: assay principles, antibody specificity, analytical performance and assay performance in disease. Additionally, the review will describe the potential user benefits of adopting these new generation FLC assays, which are designed to overcome the established limitations of existing polyclonal antibody based FLC assays. Keywords: free light chains; myeloma; point of care; turbidimetry. Introduction The key components for any kappa (κ) and lambda (λ) free light chain (FLC) assay are the detection antibodies. These antibodies ultimately determine the performance characteristics of the assay in which they are incorporated. To be defined as effective antibodies, several factors must be considered. Firstly, the antibodies can be either monoclonal or polyclonal. The use of monoclonal antibodies (mabs) results in higher lot-to-lot consistencies in assay performances, and does not need renewed immunization, purification and processing to obtain specificity, as required for polyclonal antibodies. Clearly, a substantial benefit of reduced batch variation is the potential for more reliable patient monitoring, particularly when tracking patients through disease therapy and remission. Furthermore, most mabs can be selected to have higher affinities than polyclonal antibodies and have better defined specificities, thus avoiding cross-reactivity with other proteins, including immunoglobulin bound-light chains (LC). Both κlc and λlc are, by nature, highly heterogeneous molecules. The protein sequences show high variability in the antigen-binding domains. The constant (i.e. invariable domains) of the LC proteins are coded by only one gene for κ and up to seven genes for λ and therefore may serve as the best target for mab binding to ensure full and consistent recognition of these proteins [, 2]. Besides binding to the preserved sequences of the LC proteins, mabs should bind to the exposed part of the LC protein that is hidden when LC is bound to immunoglobulin heavy chains. Several studies have described the production of mabs to FLCs that fulfill at least the criterion of binding to free and not to heavy chain-bound LC [2 5]. Using these mabs, several assays have been developed, but not all of these tests have subsequently become commercially available. In this review, two commercial methods are described which demonstrate that use of mabs for the detection of FLC in serum is comparable with polyclonal-based assays for patient diagnosis and monitoring, and have the predicted analytical performance benefits of mab-based assays. The N Latex FLC assays are nephelometric assays for the Siemens BN -systems and the Seralite assay is a rapid, lateral flow test. *Corresponding author: John P. Campbell, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B5 2TT, UK, j.p.campbell@bham.ac.uk Henk te Velthuis: Sanquin Reagents and Sanquin Research, Sanquin Blood Supply Foundation and Landsteiner Laboratory, Academic Medical Center, Amsterdam, The Netherlands Mark Drayson: Institute of Immunology and Immunotherapy, University of Birmingham, UK The N Latex FLC κ and λ assays Assay principle The N Latex FLC assays (Siemens Healthcare Diagnostic Products GmbH, Marburg, Germany) are latex-based Download Date 3/3/6 8:3 PM
3 2 te Velthuis et al.: FLC assays using monoclonal antibodies nephelometric assays for the measurement of κ and λflc in serum, Li-heparin plasma, EDTA plasma, urine and cerebrospinal fluid [5]. The assays are specifically designed for the Siemens BN systems. For the assays, panels of specific murine mabs to either κ or λflc are covalently coupled to latex beads. With the use of more than one mab in the assay, detection of all variations of LC proteins is supported. The latex beads ensure the needed sensitivity and reduce, together with the high affinity antibodies, the reaction time of the assays. Additionally, a strong detergent dissociates the sticky FLC molecules from hydrophobic surfaces and ensures recognition by the antibodies. Both FLC assays contain a short pre-reaction and a min main reaction. The pre-reaction protects the reaction from antigen excess and prevents false negative results. The short pre-reaction is only possible with the use of high affinity antibodies. The pre-reaction starts immediately when a small amount of sample is added to the reaction cuvette and should give sufficient agglutination within the given pre-reaction time. During the agglutination reaction, non-specific reactions are prevented with the use of mouse immunoglobulins and strong detergents. FLC antibody specificity For the development of the FLC assays, panels of more than 5 monoclonal mouse antibodies were created. For this, mice were immunized with polyclonal human κ and λ from multiple donors. The mabs were selected based on specificity in an ELISA system as previously described [5]. During the selection procedure more than 9% of the mabs were found to be specific for the free κ and λ molecules and non-responsive to intact immunoglobulins. After cross matching, non-competing mabs were tested on purified monoclonal and polyclonal κ and λflc. The non-competing mabs should recognize all allotypes of κflc and isotypes of λflc. The selected mabs proved responsive to monoclonal and polyclonal FLC. In the next step the mabs were covalently bound to latex beads and tested in the nephelometer. Once the final assay protocols on the BN systems were established, over 25 clinical samples were tested for κflc and λflc in serum and compared to the Freelite assays (Figure A and B) (unpublished data). There is a clear numerical difference between the methods especially for λflc. With low and very high concentrations of FLC, the methods gave results which may differ more than -fold. At low concentrations, these differences are partially explained by the gap effect in the Freelite assays (for explanation see further on). This inaccuracy in the Freelite assays strongly influences the ratio of involved/ uninvolved light chains. In Figure C, the direct comparison of the κflc/λflc ratio for both methods is shown. The overall identity for ratios identified as low, normal or increased was 86% with a Cohen s κ of.77. Within the reference ranges for the ratios, both methods show good similarity, while outside these ranges the ratios may show greater differences. The constant domains of the light chains, as indicated by the name, are well preserved, but also contain a limited number of allotypes or isotypes []. The selected mabs for the panels reacted with the constant domain of the light chains. The phenotype of monoclonal κ and λflc may differ by a yet unknown mechanism and lead to substantial variations in the structure of the light chain molecule. Monoclonal κ and λflc come in different shapes and sizes when the molecules multimerize [6 9]. The formation of these multimers may hamper or enhance recognition by the antibodies. The outcome of the measurement is based on the availability of the epitopes in the light chain molecule, more than the genetic variations in the constant domain of the FLC. Different sets of mabs may therefore lead to different results, as shown during the development of the mabs used in the Seralite assay [2]. The spearman correlation between the results of different combinations of mabs for λ was.97, but for κ the correlation was.78. Analytical performance The major advantages of the use of mabs in the assays are the reduced variability between the lots, and the high affinity binding to the LC molecules. The lot-to-lot consistency of the assays was demonstrated to be 7.3% for κflc and % for λflc [5,, ]. Pretorius et al. [] and Lock et al. [] tested only a limited number of lots, but when samples were measured on more combinations of calibrators and reagents these findings were confirmed (Figure 2). The N Latex FLC assays demonstrated a high lot-to-lot consistency, which allows for flexible calibration by combining different lots of latex reagents, supplementary reagent, standard and controls. Good precision over the whole measuring range is of importance for calculation of the involved/uninvolved FLC ratio to accurately predict progression of smoulding multiple myeloma patients to active malignant disease [2]. The N Latex FLC assays showed good precision with %CVs < 5% 7% over the whole measuring range, whereas Freelite assays may have higher imprecision of up to 4% at very low concentrations [5, ], probably due to dilution anomalies, that is, the so-called FLC gap Download Date 3/3/6 8:3 PM
4 te Velthuis et al.: FLC assays using monoclonal antibodies 3 A, B,,, λflc, mg/l λflc, mg/l.. C.,, κflc, mg/l.,, κflc, mg/l,,,, N Latex FLC κ/λ ratio....,, Freelite κ/λ ratio,, Figure : Parallel measurement of 255 routine serum samples with the Freelite (A) and the N Latex (B) κflc and λflc assays and the κflc/λflc ratio comparison between the methods (C). In Figure A and B, the dotted horizontal and vertical lines indicate the reference ranges for the assays and the diagonal lines indicates the area with normal κflc/λflc ratios. In Figure C, the diagonal line indicates y = x. In this figure 44 samples are not included because either ratio was designed zero by the technician. effect [2]. The N Latex FLC assays do no suffer from the gap effect. The N Latex FLC assays show good linearity for κ and λflc within the initial measuring dilution, but also for clinical samples with concentrations of κ and λflc far above this range [5,, 3]. The N Latex FLC applications on the BN systems have built-in pre-reaction protocols to secure antigen excess protection. This protocol is highly effective for both κ and λflc. However, certain monoclonal FLC samples show a non-linear dilution behavior, the result in the next dilution providing a higher result than expected [, 4]. Jacobs et al. [4] studied the effect of sample dilution on recovery by N Latex FLC and Freelite assays, and similar to the study by Vercammen et al. using Freelite [5], showed that the detection of especially κflc is significantly hindered by the presence of high concentrations of M-proteins [4, 5]. The detection of FLC in healthy donors Download Date 3/3/6 8:3 PM
5 4 te Velthuis et al.: FLC assays using monoclonal antibodies A κflc, mg/l lots 2 9 B λflc, mg/l lots κflc, mg/l lot λflc, mg/l lot Figure 2: Lot to lot consistency of the N Latex κflc (A) and λflc (B) assays. From: Ref. [5]. with at least 5-fold molar excess of bound LCs to heavy chains in immunoglobulins compared to free, unbound, LC gives no interference. When there is a high concentration of monoclonal intact immunoglobulin present, the ratio of bound versus FLC shifts to even higher numbers and the ratio bound versus free may easily exceed 5- fold excess. There is always a chance that part of the monoclonal intact immunoglobulin is not correctly folded and part of the bound LC is exposed. If one epitope is exposed, part of the reagent is blocked by this bound LC, which results in false-low FLC concentrations in the initial dilution of the assay. The exposed epitope thus interferes with the reaction. The true concentration can only be given at higher dilutions of the samples. This interference is patient, that is, sample, specific and found with both Freelite and N Latex FLC assays [4]. VanDuijn et al. described a new mass spectrometry (MS) analysis of the light chains in serum [6]. The correlations between the MS method, N Latex FLC assays and Freelite were very good, but the MS method requires intensive processing before analysis because all bound LCs in intact immunoglobulins need to be discarded. The MS method also revealed gross overestimation by Freelite measured on the Siemens BNII and some overestimation by the N Latex FLC. The difference between Freelite and N Latex FLC in this context is remarkable, because the concentrations of the calibrators for the N Latex FLC are derived from one single lot of the Freelite assays. For the calibration of the N Latex FLC assays, the first master calibrator was made in 28 in the same formulation as the calibrator and controls of the kit and stored at 8 C. In 28, this master calibrator was calibrated to the one lot of Freelite assays. Due to the significant variability of Freelite kits [7], the in-house master calibrator showed unacceptable high variability when measured on successive lots of Freelite. All working standards are derived from this one-time calibrated lot of master calibrator. The master calibrator is controlled each year for drift by measuring fresh samples from 2 donors from the blood bank population. The samples come from the same donor population that was used to establish reference ranges for these assays. ANOVA gauge repeatability and reproducibility measurements were performed to determine the total amount of variability of the BN system itself. They were compared to the variability of the FLC measurement itself. The measurements were performed on 3 BN systems with 3 κflc and 92 λflc results. The variation for κflc was 4.4% and for λflc was 3.% (unpublished data). Reference intervals were created with 253 EDTA plasma samples and 4 serum samples from normal healthy blood bank donors aged 8 7 years: κflc mg/l, λflc mg/l and FLC ratio.3.56 [5]. Jacobs et al. and Tate et al. studied patients with renal impairment with chronic kidney disease (CKD) class 5 [8, 9]. As κ and λflc increased significantly but proportionally with every CKD increment, the N Latex FLC does not need special reference ranges for the FLC ratio in patients with renal impairment. Download Date 3/3/6 8:3 PM
6 te Velthuis et al.: FLC assays using monoclonal antibodies 5 Assay performance in disease The international guidelines indicate that the measurements of FLC should be combined with a clinical history and other diagnostic tests to reach high clinical sensitivity and specificity for different disease states [2, 7]. Just like the Freelite assays, the N Latex FLC assays show diagnostic and clinical limitations partly due to the nature of the FLC proteins which may lead to reduced recognition [, 2 22] Therefore FLC assays should be used in conjunction with other laboratory tests [3, 2]. In the diagnosis of AL amyloidosis, when the FLC measurement is combined with serum and urine protein electrophoresis and immunofixation (IFE) the diagnostic sensitivity, that is, the identification of the amyloidogenic clone, is reported to be 98% for both N Latex and Freelite assays [23, 24]. When used in daily practice, the correlation and concordance rate for screening of patients with plasma cell dyscrasias between Freelite, serum-ife and N Latex FLC was good [8,, 3, 6, 2, 22, 25]. Although the studies were performed with limited numbers of patients, the N Latex FLC showed 97% % clinical specificity (true negative) and 6% 65% sensitivity (true positive), compared to 94% 97% and 6% 72% for Freelite, respectively, when compared to serum-ife [2, 22]. The guidelines for monitoring disease states are based on the Freelite assays on the Siemens BNII system [7]. Numerical differences in the FLC ratio between the assays, partly due to the gap effect in the Freelite assays and to differences in λflc concentration between N Latex and Freelite assays mean that guideline response criteria based on Freelite assays may not fully apply to the N Latex FLC assays [, 7, 26 33]. However, N Latex FLC can accurately be used for prognostic stratification in AL amyloidosis patients based on the guidelines by Comenzo et al., as demonstrated by Mollee et al. and Palladini et al. [23, 24, 34]. The survival rate according to a revised staging system can be predicted in these patients, but the response assessment needs to be further evaluated in larger studies [23, 24]. N Latex FLC is fairly new to the market and not all diseases have been specifically studied with these assays. More studies are needed to demonstrate the clinical performance of the tests. The Seralite dual κ and λ assay Seralite (Abingdon Health, York, UK) is a rapid and portable diagnostic device enabling the simultaneous quantitative measurement of serum κ and λflc. Seralite generates FLC results in a rapid timeframe and is designed to accelerate clinical decision-making near the patient. Using highly-specific and extensively validated mouse anti-human κ and anti-human λ mabs [2], Seralite is the first available FLC immunoassay to use a competitive inhibition format to prevent against false negatives caused by antigen-excess, a feature of non-competitive FLC assays that arises as a result of high FLC levels in patients with plasma cell dyscrasias. Assay principle Serum is mixed gently with sample application buffer provided with the Seralite kit. As illustrated in Figure 3, an aliquot is then added to the Seralite device, where it initially flows through a sample pad, and then onto a conjugate release pad containing gold-nanoparticle labeled anti-κ and anti-λ mabs. These mabs rehydrate, and together with the diluted sample, flow across a test membrane. At the end of the test membrane are two test lines, which contain purified κflc or λflc. The flow of sample and gold-labeled mabs is allowed to continue for min during which time any FLC in the sample will bind to its respective gold-labeled mab; the higher the concentration of FLC in the sample, the less gold-labeled mab will bind to the test line, and vice versa. The line intensity of the binding is determined by the Seralite reader which also times the incubation, calculates the concentration of FLCs in the sample (from a stored calibration curve) and calculates the FLC ratio. The Seralite initial calibration curve for κ and λflc is mg/l. If the FLC level in a sample is above 2 mg/l, a further sample dilution of one in 2 extends the upper range of the assay to 4 mg/l This broad Seralite calibration range, combined with the elimination of antigen excess, reduces the need for frequent sample dilution and is designed to improve laboratory workflow. The calibrators used for Seralite are traceable to an original calibrator, which was tested on multiple batches of Freelite, as there is no recognized international standard for FLC. FLC antibody specificity Over the past 2 years or so, numerous attempts have been made to generate anti-flc mabs that may be suitable for use in FLC immunoassays [3 5, 35]. To be efficacious, anti-flc mabs must identify epitopes that are exposed on FLC but hidden on LCs bound to heavy chains; thus eliminating mab cross-reactivity with whole Download Date 3/3/6 8:3 PM
7 6 te Velthuis et al.: FLC assays using monoclonal antibodies Figure 3: Schematic view of a single Seralite device. Refer to text for assay principle. immunoglobulin, a feature of polyclonal antibody based assays [35]. Crucially, the mabs must detect each unique FLC secreted from a diverse range of plasma cells from all patients. This mission is made more difficult by the limited number of constant domain epitopes available on FLCs, and by the polymerisation of FLCs, particularly λ, which thus reduces the availability of mab binding sites. As of yet, suitable mabs that meet these criteria have not been met as these mabs either: failed to identify monoclonal FLCs in patient samples, or were not validated against thousands of samples containing a wide variety of different monoclonal proteins [35, 36]. Seralite utilizes anti-flc mabs which have been extensively validated against thousands of patient samples, firstly in a multi-plex bead array assay [2], and more recently in Seralite. Initially, the mabs were shown to successfully detect monoclonal FLC where present and identifiable by the gold standard of urine-ife, in 3,9 consecutive urine samples. The mabs also identified monoclonal FLC in serum from consecutive clinical samples. Half of these samples contained monoclonal FLC, detected in paired urine samples by IFE, and it was found that the mabs identified an abnormal FLC ratio in all of these samples and showed excellent diagnostic concordance with course of disease assessed by other laboratory tests of disease activity and clinical course documented in myeloma trial databases. Furthermore, the assay correlated excellently with Freelite for the quantitation of normal polyclonal FLC in serum from healthy donors. Thus, the mabs appear to be at least close to the ideal of detecting FLC from all plasma cell clones in all patients [2]. Analytical performance The analytical performance of Seralite is in submission in a separate publication and representative data is presented herein as an illustration of assay performance. Total imprecision has been assessed by the analysis of samples containing a range of FLC concentrations (5 74 mg/l). These were tested, as per the directions provided in the test kit, by three operators, on two Seralite readers, using two different batches of test kits, on a total of 6 devices. There were no significant differences between readers, operators or kit lots and percentage CVs were between 9% and 2%. No significant interference was observed upon assessment of common interference agents, including cholesterol, triglyceride, bilirubin and hemoglobin added at final concentrations of 5.2,.3 mmol/l, 342 μmol/l and 2 g/l, respectively to samples with normal and elevated FLC levels. Together, these findings replicated Seralite mab performance in a prior report [2]. High levels of FLC in serum from patients with plasma cell dyscrasias have been shown to result in lower than expected FLC levels; a result of antigen excess that affects direct turbidimetric and nephelometric immunoassays which also gives rise to non-linear dilutions [29, 32]. To prevent against Download Date 3/3/6 8:3 PM
8 te Velthuis et al.: FLC assays using monoclonal antibodies 7 antigen excess, Seralite utilizes a competitive inhibition format, which means that as FLC levels increase, available binding sites on the gold-labeled mab become saturated and the mab is inhibited from binding to the immobilized FLC antigen on the membrane; a false negative due to antigen excess is thus not possible [37]. To demonstrate elimination of antigen excess on Seralite, Table illustrates a number of case studies whereby antigen excess was evident on Freelite, but not on Seralite. Given the broad extremes exhibited by FLCs in the general population ranging from below 2 mg/l in immune suppression to over g/l in multiple myeloma this is an important technical development that will ensure protection against antigen excess. Assay performance in disease Seralite correlates with Freelite in samples from healthy donors (Figure 4A C), (unpublished data) where both assays exhibit similar quantitation of absolute polyclonal κ and λflc, and FLC ratio. The results are significantly correlated (κflc, p <.; λflc, p <.; FLC ratio, p =.7). Unlike Freelite, Seralite satisfactorily identifies FLC in patients with low levels of uninvolved FLC (Figure 4, panels D and E), and does not exhibit the gaps between ~2 mg/l and ~7 mg/l that are seen in the lower end of the Freelite assay range [2]. This feature of Freelite must be taken into account when monitoring patients with plasma cell dyscrasias; an artefactual shift from 7 mg/l to mg/l in uninvolved Freelite FLC level will cause an artefactual seven-fold change in FLC ratio. Illustrated in the panel D and E of Figure 4 are uninvolved FLC in 247 myeloma patients at disease presentation; the Freelite gaps below 7 mg/l are clearly identifiable. In clinical practice, the FLC difference (involved FLC minus uninvolved FLC) is used to monitor response to therapy and monitor for relapse. Illustrated in panel F of Figure 4 is the FLC difference calculated for 4 patients at myeloma presentation; all patients presented with a FLC paraprotein visible in serum-ife or in a paired urine sample by IFE. It can be seen that Seralite and Freelite exhibited diagnostic concordance, but quantitative estimation of monoclonal FLCs from neoplastic plasma cells was often divergent. Thus, in order to compare FLC levels between two samples from the same patient, it is important that same assay method is used; as is the case for monitoring whole paraprotein levels. In a separate study, larger cohorts of myeloma patients (n = 476) with light chain only myeloma, non-secretory myeloma, and intact immunoglobulin myeloma (IgA, IgG, IgD) were monitored through disease presentation, response to therapy, remission and relapse [38]. Seralite provided excellent diagnostic concordance with Freelite in these patient groups [38]. Seralite clinical validation was extended to assess serial serum FLC measurements in patients who presented with IgA or IgG myeloma, who developed a relapse characterized by an increase in FLC (Δ > mg/l and > 25%) without a corresponding increase in the heavy chain level, a phenomenon termed serum FLC escape (LCE escape) [39]. Seralite identified an increase in the involved FLC and abnormal FLC ratio in all of these patients at LCE escape, and again demonstrated excellent diagnostic concordance with the Freelite assay for κ and λflc levels [39]. The clinical utility of Seralite has also been demonstrated for diagnosing myeloma kidney in 288 patients with acute kidney injury (biopsy confirmed and all glomerular filtration rates < 5 ml/min). Seventy-eight of these patients had a confirmed myeloma diagnosis and all were identified as having elevated involved FLC and an abnormal FLC ratio on Seralite ; Seralite had excellent diagnostic concordance with Freelite in all serum samples tested [4]. Taken together, these retrospective studies demonstrate that Seralite is effective in diagnosing and Table : Results from five samples that had antigen excess with Freelite assay. Freelite, mg/l Seralite, mg/l Freelite, mg/l Seralite, mg/l Sample κ (initial dilution) κ (final result) κ (initial dilution) κ (final result) λ (initial dilution) λ (final result) λ (initial dilution) λ (final result) A < 2.5 < 2.5 B < 2.5 < > 2 39,48. C > D ,594. > 2 22, E.3 4,723 > 2 32, < 2.5 < 2.5 Initial results with Seralite and Freelite assays are shown. Samples were then diluted at a higher dilution as recommended with the Freelite assay when antigen excess is suspected. Download Date 3/3/6 8:3 PM
9 8 te Velthuis et al.: FLC assays using monoclonal antibodies A B C κflc in healthy donors λflc in healthy donors κ:λflc ratio in healthy donors Freelite, mg/l Freelite, mg/l Freelite, κ:λ Seralite, mg/l Seralite, mg/l Seralite, κ:λ Uninvolved κflc in myeloma patients with a λ paraprotein Uninvolved λflc in myeloma patients with a κ paraprotein D E F FLC difference at myeloma diagnosis,, Freelite, mg/l Freelite, mg/l Freelite, mg/l κ diagnosis λ diagnosis Seralite, mg/l Seralite, mg/l, Seralite, mg/l, Figure 4: Comparison between Seralite and Freelite assays. Plots A, B and C show comparative data for κflc, λflc and FLC ratio in healthy donors (n = 44). Plot D illustrates uninvolved κflc in myeloma patients with a λ paraprotein (n = 9). Plot E illustrates uninvolved λflc in myeloma patients with a κ paraprotein (n = 38). Plot F shows comparative results for FLC difference (involved minus uninvolved), in 4 myeloma patients at diagnosis; 67 patients had κflc in serum-ife, and 47 patients had λflc in serum-ife. Dotted lines represent Freelite reference range for normal healthy donors. monitoring plasma cell dyscrasias. The aforementioned studies have been presented at recent hematology meetings and, are in submission for publication elsewhere. Future independent studies will address the prospective utility of Seralite in clinical practice. In conclusion, Seralite is a rapid and portable diagnostic device that facilitates near-patient quantitation of FLC in serum. Using highly-specific and extensively validated anti-κ and anti-λ mabs [2], Seralite is designed to accelerate clinical decision-making and is the first available FLC immunoassay to use a competitive inhibition format to prevent against antigen-excess. Generation of rapid FLC results may empower clinicians to establish disease status and make informed treatment decisions more quickly and efficiently. Conclusions FLC measurements play a pivotal role in the screening, monitoring and prediction of progression of disease for patients with plasma cell dyscrasias. The great number of publications on FLC measurements demonstrates that patient management greatly benefits from the use of FLC assays. The introduction of the monoclonal-based FLC assays has opened new perspectives for the clinical laboratory and allows rapid testing in the clinic. It has demonstrated the analytical pro- and cons of the old and the new assays, but it also highlighted that the monoclonal κ and λlc proteins come in many forms and the same FLC may be measured at different concentrations depending on the assay. Although the correlations and concordance between the assays are Download Date 3/3/6 8:3 PM
10 te Velthuis et al.: FLC assays using monoclonal antibodies 9 good between the polyclonal and monoclonal-based FLC assays, the results are not interchangeable, as is well established for different methods to detect whole M-proteins. Indeed, during the development of the Seralite assays, it became apparent that the measured concentrations of FLC in serum depend on the antibodies used for the assays [2]. Crucially, however, the monoclonal-based assays herein provide similar reaction patterns to the polyclonal-based assays, and high levels of involved monoclonal FLC are identified at disease presentation, show a reduction during successful disease therapy, and an increase at disease progression. Thus, an adequate period of parallel testing should enable the continued accurate follow up of the patient if changing from one test method to another. Benefits of using mabs assays include that users evade lot-to-lot variations as seen even with successive batches of polyclonal antibodies on Freelite. Indeed, within the collection of Freelite assays, customers notice differences in outcome in EQAS studies when the assays are performed on different systems [2]. This shows that in a similar manner to whole M-protein assays results for different FLC assays on different clinical analyzers are not interchangeable. At the same time, the differences between the methods demonstrate how difficult standardization of the FLC assays will be. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Research funding: None declared. Employment or leadership: None declared. Honorarium: None declared. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication. JC and MD have shares in Abingdon Health Ltd. References. LeFranc M-P, LeFranc G. The immunoglobulin factsbook. London: Academic Press, Campbell JP, Cobbold M, Wang Y, Goodall M, Bonney SL, Chamba A, et al. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine. J Immunol Methods 23;39: Abe M, Goto T, Kennel SJ, Wolfenbarger D, Macy SD, Weiss DT, et al. Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies. Am J Clin Pathol 993;: Nakano T, Nagata A. ELISAs for free human immunoglobulin light chains in serum: improvement of assay specificity by using two specific antibodies in a sandwich detection method. J Immunol Methods 24;293: te Velthuis H, Knop I, Stam P, van den Broek M, Klaasse Bos H, Hol S, et al. N Latex FLC new monoclonal high performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2;49: Berggard I, Peterson PA. Polymeric forms of free normal kappa and lambda chains of human immunoglobulin. J Biol Chem 969;244: Abraham RS, Charlesworth MC, Owen BA, Benson LM, Katzmann JA, Reeder CB, et al. Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. Clin Chem 22;48: Di Noto G, Cimpoies E, Dossi A, Paolini L, Radeghieri A, Caimi L, et al. Polyclonal versus monoclonal immunoglobulin-free light chains quantification. Ann Clin Biochem 25;52: Graziani M, Merlini G, Petrini C. Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 23;4: Pretorius CJ, Klingberg S, Tate J, Wilgen U, Ungerer JP. Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann Clin Biochem 22;49: Lock RJ, Saleem R, Roberts EG, Wallage MJ, Pesce TJ, Rowbottom A, et al. A multicentre study comparing two methods for serum free light chain analysis. Ann Clin Biochem 23;5: Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 24;5:e Sasson SC, McGill K, Wienholt L, Carr A, Brown DA, Kelleher AD, et al. Comparison of the Freelite serum free light chain (SFLC) assay with serum and urine electrophoresis/immunofixation and the N Latex FLC assay. Pathology 25;47: Jacobs JF, Hoedemakers RM, Teunissen E, van der Molen RG, Te VH. Effect of sample dilution on two free light chain nephelometric assays. Clin Chim Acta 22;43: Vercammen M, Meirlaen P, Broodtaerts L, Vande B, I, Bossuyt X. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clin Chim Acta 2;42: VanDuijn MM, Jacobs JF, Wevers RA, Engelke UF, Joosten I, Luider TM. Quantitative Measurement of Immunoglobulins and Free Light Chains Using Mass Spectrometry. Anal Chem 25;87: Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 29;23: Jacobs JF, Hoedemakers RM, Teunissen E, Te VH. N Latex FLC serum free light-chain assays in patients with renal impairment. Clin Chem Lab Med 24;52: Tate J, Bazeley S, Klingberg S, Pretorius CJ, Hutchison C, Mollee P. Comparison of the Freelite and N Latex serum free light chain (FLC) assays in chronic kidney disease. Clin Biochem Rev 22;33:S4. 2. Tate J, Mollee P. Towards improved measurement of serum free light chains: clinical and laboratory issues. Biochimica Clinica 23;37: Hoedemakers RM, Pruijt JF, Hol S, Teunissen E, Martens H, Stam P, et al. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to Download Date 3/3/6 8:3 PM
11 te Velthuis et al.: FLC assays using monoclonal antibodies polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med 2;5: Kim HS, Kim HS, Shin KS, Song W, Kim HJ, Kim HS, et al. Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy. Biomed Res Int 24;24: Mollee P, Tate J, Pretorius CJ. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clin Chem Lab Med 23: Palladini G, Bosoni T, Milani P, Pirolini L, Foli A, Li Bergolis F, et al. Use of the novel monoclonal assay for the measurement of circulating free light chain in the diagnosis, prognostication of survival and assessment of response to therapy in AL amyloidosis. Blood 22;2:393a. 25. Schneider N, Wynckel A, Kolb B, Sablon E, Gillery P, Maquart FX. [Comparative analysis of immunoglobulin free light chains quantification by Freelite (the binding site) and N Latex FLC (Siemens) methods]. Ann Biol Clin (Paris) 23;7: Briand PY, Decaux O, Caillon H, Grosbois B, Le TA, Guenet L. Analytical performance of the serum free light chain assay. Clin Chem Lab Med 2;48: de Kat Angelino CM, Raymakers R, Teunesen MA, Jacobs JF, Klasen IS. Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin Chem 2;56: Daval S, Tridon A, Mazeron N, Ristori JM, Evrard B. Risk of antigen excess in serum free light chain measurements. Clin Chem 27;53: Bosmann M, Kossler J, Stolz H, Walter U, Knop S, Steigerwald U. Detection of serum free light chains: the problem with antigen excess. Clin Chem Lab Med 2;48: Mead GP, Carr-Smith HD. Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin Chem 2;56: Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 27;376: Tate J, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay analytical issues. Clin Biochem Rev 29;3: Bakker AJ, Bierma-Ram A, Elderman-van der Werf C, Strijdhaftig ML, van Zanden JJ. Quantitation of serum free light chains. Clin Chem 29;55: Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 22;26: Davern S, Tang LX, Williams TK, Macy SD, Wall JS, Weiss DT, et al. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol 28;3: Drayson M, Carr-Smith H. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med 22;5: Wild D. The immunoassay handbook, 3rd ed. Amsterdam and London: Elsevier, Campbell JP, Stride AE, Heaney J, Cobbold M, Wang Y, Goodall M, et al. Validation of a rapid lateral-flow test for the diagnosis and monitoring of immunoglobulin free light chains: retrospective analysis of sera from patients with plasma cell dyscrasias. Clin Chem 23;59:A Campbell JP, Stride AE, Brioli A, Goodall M, Morgan GJ, Drayson MT. Seralite (c) rapid point-of-care detection of free light chain escape, non-secratory relapse and light chain only relapse in multiple myeloma. Blood 23;22: Campbell JP, Stride AE, Cobbold M, Wang Y, Goodall M, Bonney SL, et al. Rapid test to identify myeloma kidney by measurement of serum free light chains. Clin Lymphoma Meyolma Leuk 23;3:454. Download Date 3/3/6 8:3 PM
Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory
Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Learning Objectives Compare traditional
Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies
Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies Montgomery Lobe, MD, and Donald Pasquale, MD Abstract Monoclonal gammopathies are characterized by production of monoclonal
Journal of Immunological Methods
Journal of Immunological Methods 391 (2013) 1 13 Contents lists available at SciVerse ScienceDirect Journal of Immunological Methods journal homepage: www.elsevier.com/locate/jim Research paper Development
Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy
Hutchison et al. BMC Clinical Pathology 2012, 12:12 TECHNICAL ADVANCE Open Access Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy
Sharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma
Clinical Chemistry 56:1 16 20 (2010) Clinical Case Study Sharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma Kazunori Murata, 1 Raynell J. Clark, 1 Karen S. Lockington,
Assessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs Population
Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol 36, no. 2, 2006 157 Assessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs
Serum Free Light Chain Assays
Freelite Serum Free Light Chain Assays An aid to the diagnosis of: Light Chain (Bence Jones) Multiple Myeloma (LCMM) Nonsecretory Multiple Myeloma (NSMM) AL amyloidosis Light Chain Deposition Disease (LCDD)
Analytically coherent
ZO M OCTOBER 2017 N 7 sebia FLC Free light chain testing coherent with electrophoretic methods Analytically coherent SPE: 3.1 g/l FLC Nephelometry: 32.2 g/l FLC ELISA: 3.1 g/l Principle The sebia FLC Kappa
Polyclonal versus monoclonal immunoglobulin-free light chains quantification
Original Article Annals of Clinical Biochemistry 2015, Vol. 52(3) 327 336! The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563214553808 acb.sagepub.com
Serum Free Light Chain Analysis
Serum Free Light Chain Analysis Rajeevan Selvaratnam, Jing Cao and Amy B. Karger Introduction In healthy individuals, plasma cells originating from the bone marrow produce immunoglobulin molecules composed
Measuring Myeloma in the LAB. BL Ferry Clinical Lead Sept 15 th 2014
Measuring Myeloma in the LAB BL Ferry Clinical Lead Sept 15 th 2014 Oxford Immunology Laboratory Clinical Immunology Churchill WHAT DO WE MEASURE AND HOW? Clinical Immunology Churchill Serum proteins Proteins
Serum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma
Serum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma Kelly Endean PhD Scientific Affairs Manager, The Binding Site Focus of this talk An introduction to heavy-light chain
Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test
Heaney et al. BMC Nephrology (2017) 18:247 DOI 10.1186/s12882-017-0661-z RESEARCH ARTICLE Open Access Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free
Summary. Original Article. Postepy Hig Med Dosw (online), 2017; 71: e-issn
Postepy Hig Med Dosw (online), 2017; 71: 40-46 e-issn 1732-2693 www.phmd.pl Original Article Received: 2016.03.19 Accepted: 2016.08.19 Published: 2017.01.22 DOI: 10.5604/17322693.1229346 Authors Contribution:
Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests
research paper Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests Jennifer L. J. Heaney, 1 John P. Campbell, 1 Anne E. Griffin, 1 Jane Birtwistle,
Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples
Immunopathology / Electrophoresis of Unconcentrated Urine Samples Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples Anja C. Roden, MD,
Elevated Immunoglobulins and Paraproteins
Elevated Immunoglobulins and Paraproteins NWL Pathology GP Study Afternoon Thursday 19 th October 2017 Dr Aristeidis Chaidos Consultant Haematologist and Honorary Senior Clinical Lecturer Hammersmith Hospital,
PeliClass human IgG subclass ELISA kit Enzyme-linked immunosorbent assay
PeliClass human IgG subclass ELISA kit Enzyme-linked immunosorbent assay Catalog No: M1551 Size: six pre-coated 8-well strips for each of the four IgG subclasses Test description The PeliClass human subclass
What do you do, with an M protein?
What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily
Keywords: exercise; free light chains; immunoglobulins; renal function. Introduction
Clin Chem Lab Med 2015; aop John P. Campbell a, *, Thijs M.H. Eijsvogels a, Yanyun Wang, Maria T.E. Hopman and Joannes F.M. Jacobs Assessment of serum free light chain levels in healthy adults immediately
PAB PRINCIPLE. Kit Reorder # ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE
SYNCHRON CX System(s) Chemistry Information Sheet Copyright 2008 Beckman Coulter, Inc. Prealbumin Kit Reorder # 475106 For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by: Date Reviewed by: Date PRINCIPLE
Cyfra 21-1 IRMA. Product information Information about other products is available at: Userś Manual DE52100
Product information Information about other products is available at: www.demeditec.com Userś Manual Cyfra 21-1 IRMA The CYFRA 21.1 IRMA system provides a direct in vitro quantitative determination of
H-ferritin (Human) ELISA Kit
H-ferritin (Human) ELISA Kit Catalog Number KA0211 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of
Human Immunoglobulin Free Light Chains Kappa and Lambda ELISA Kit
Human Immunoglobulin Free Light Chains Kappa and Lambda ELISA Kit Cat. No.:DEIA4632 Pkg.Size:96 T Intended use The Human Immunoglobulin Free Light Chains Kappa and Lambda ELISA kit contains two sandwich
Assessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin / Ratios
Clinical Chemistry 55:9 1646 1655 (2009) Cancer Diagnostics Assessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin / Ratios Arthur R. Bradwell, 1,2* Stephen J.
Management of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison
Management of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison Consultant Nephrologist, Hawke s Bay DHB, NZ Senior Lecturer, University of Birmingham, Birmingham, UK Why are nephrologists interested
HUMAN IMMUNOGLOBULIN FREE LIGHT CHAINS κ AND λ ELISA. Product Data Sheet. Cat. No.: RD R. For Research Use Only
HUMAN IMMUNOGLOBULIN FREE LIGHT CHAINS κ AND λ ELISA Product Data Sheet Cat. No.: RD194088100R For Research Use Only Page 1 of 36 VERSION 98 110511 18 CONTENTS 1. INTENDED USE 3 2. STORAGE, EXPIRATION
AAG PRINCIPLE SPECIMEN. REF (150 tests) ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE
IMMAGE Immunochemistry Systems Chemistry Information Sheet Copyright 2010 Beckman Coulter, Inc. Alpha 1 -Acid Glycoprotein REF 447780 (150 tests) For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by:
For the quantitative detection of human IL6 in serum, plasma, cell culture supernatants and urine.
m andw da a For the quantitative detection of human IL6 in serum, plasma, cell culture supernatants and urine. general information Catalogue Number Product Name Species cross-reactivity Range (calibration
NAG-1 (GDF-15, MIC-1) Prostate Cancer ELISA kit
NAG-1 (GDF-15, MIC-1) Prostate Cancer ELISA kit Catalog Number: NG1 Store at -0 C. FOR RESEARCH USE ONLY v. 1081 Introduction This sandwich ELISA kit is for determination of NAG-1 (GDF-15, MIC-1) levels
Immunoassay Kit Catalog # KCA0021. Canine. C-Reactive Protein
Immunoassay Kit Catalog # KCA0021 Canine C-Reactive Protein BioSource International, Inc. 542 Flynn Road Camarillo, California 93012 USA Tel: 805-987-0086 800-242-0607 FAX: 805-987-3385 email: tech.support@biosource.com
Nephelometry and turbidimetry are liquid based immunoassays based on the measurement of scattered or absorbed light.
1 Nephelometry and turbidimetry are liquid based immunoassays based on the measurement of scattered or absorbed light. Light scattering is the physical phenomenon resulting from the interaction of light
Magnetic Luminex Assay
Magnetic Luminex Assay Mouse Immunoglobulin Isotyping Catalog Number LXMIGMG For the simultaneous quantitative determination of multiple mouse immunoglobulin isotype concentrations in cell culture supernates,
Application Note for Gentian Cystatin C Immunoassay on. ABX Pentra 400 1, Horiba Medical 1 v03en-june 2011
Page 1 of 5 Application Note for Gentian Cystatin C Immunoassay on For in vitro diagnostic use only ABX Pentra 400 1, Horiba Medical 1 v03en-june 2011 Intended Use The Gentian Cystatin C Immunoassay is
Assays and Strategies for Immunogenicity Assessment. Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen
Assays and Strategies for Immunogenicity Assessment Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen General Antibody Assay Strategy Correlation of clinical findings
Immunological Techniques in Research and Clinical Medicine. Philip L. Cohen, M.D. Chief of Rheumatology, LKSOM 10 March 2016
Immunological Techniques in Research and Clinical Medicine Philip L. Cohen, M.D. Chief of Rheumatology, LKSOM 10 March 2016 Antibodies Remarkable Tools for Research and Diagnosis You can make an antibody
Metrological Traceability and Assay Standardization in Laboratory Medicine. STRESA, ITALY May 24, 2013
Metrological Traceability and Assay Standardization in Laboratory Medicine STRESA, ITALY May 24, 2013 Standardization of ctni: Is there a light at the end of the tunnel? Jill Tate Pathology Queensland
Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
Luminex Assay. Mouse Immunoglobulin Isotyping. Catalog Number LXIGM
Luminex Assay Mouse Immunoglobulin Isotyping Catalog Number LXIGM For the simultaneous quantitative determination of multiple mouse immunoglobulin isotype concentrations in cell culture supernates, serum,
IgG Antibodies To Toxoplasma. Gondii ELISA Kit
IgG Antibodies To Toxoplasma Catalog No: IRAPKT1405 Gondii ELISA Kit Lot No: SAMPLE INTENDED USE The Toxoplasma IgG ELISA is intended for use in evaluating a patient s serologic status to Toxoplasma gondii
Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio
Elmer ress Original Article J Clin Med Res. 2017;9(1):46-57 Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio Gurmukh
Human IgG Rubella ELISA Kit
Human IgG Rubella ELISA Kit Catalog No: IRAPKT2020 Lot No: SAMPLE INTENDED USE The Rubella IgG ELISA is intended for use in evaluating a patient s serologic status to the rubella virus infection. It is
Application Note AN001
Testing hybridoma supernatants with the Spots On Dots Antibody Screening Kit Application Note AN1 Table of Contents Overview... 2 Figure 1. Screening of hybridomas raised against peptide antigens... 3
Human IgG ELISA Quantitation Set
Human IgG ELISA Quantitation Set Cat. No. E80-104 Components Supplied Affinity purified Goat anti-human IgG-Fc Coating Antibody A80-104A, 1 ml at 1 mg/ml Human Reference Serum, RS10-110-4, 0.1 ml HRP Conjugated
Bio-Plex suspension array system
Multiplex Assays Bio-Plex suspension array system tech note 64 Profiling of Human, Canine, and Rat Urine Samples Using Bio-Plex Pro RBM Kidney Toxicity Assays L. Stephen, H. Schnaars, K. Marshall, H. Akey,
See external label 2 C-8 C Σ=96 tests Cat # 5201Z CARCINOEMBRYONIC ANTIGEN (CEA) ENZYME IMMUNOASSAYTEST KIT CEA ELISA. Cat # 5201Z
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels
Published Ahead of Print on February 1, 2018, as doi:10.3324/haematol.2017.184226. Copyright 2018 Ferrata Storti Foundation. Cytogenetic aberrations in multiple myeloma are associated with shifts in serum
This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed.
MGUS This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed. What is MGUS? Monoclonal gammopathy of undetermined significance, or
PRL (Human) ELISA Kit
PRL (Human) ELISA Kit Catalog Number KA0217 96 assays Version: 02 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of the Assay...
Introduction. Point. Keywords: electrophoresis; Hevylite; IgA; immunoglobulin; monoclonal protein.
Clin Chem Lab Med 2015; aop Point Josie A.R. Evans*, Ellen L. Jenner, Hugh D. Carr Smith, Oscar Berlanga and Stephen J. Harding Quantification of β-region IgA monoclonal proteins shouldwe include immunochemical
Performance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins
Immunopathology / SEBIA CAPILLARYS 2 PARAPROTEIN DETECTION Performance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins Zhaohai Yang, MD, PhD, Keith Harrison, MD,
colorimetric sandwich ELISA kit datasheet
colorimetric sandwich ELISA kit datasheet For the quantitative detection of mouse Interleukin 6 (IL6) concentrations in serum, plasma and cell culture supernatants. general information Catalogue Number
Immunoglobulins. Harper s biochemistry Chapter 49
Immunoglobulins Harper s biochemistry Chapter 49 Immune system Detects and inactivates foreign molecules, viruses, bacteria and microorganisms Two components with 2 strategies B Lymphocytes (humoral immune
ImmuLux Human IL-6 Fluorescent ELISA Kit
INSTRUCTIONS ImmuLux Human IL- Fluorescent ELISA Kit 3747 N. Meridian Road P.O. Box 7 Rockford, IL 05 840 53w Product Description Number Description 840 ImmuLux Human IL- Fluorescent ELISA Kit The Pierce
Why do LC MS and LBA
Why do LC MS and LBA results differ? A literature evaluation 18 November 2015 Nico van de Merbel An overview In most published BA methods for large molecules, no comparison of platforms (LBA vs LBA, LBA
FORENSIC SEROLOGY. Chapter PRENTICE HALL 2008 Pearson Education, Inc. Upper Saddle River, NJ 07458
Chapter 8 FORENSIC SEROLOGY 8-1 Nature of Blood The word blood refers to a highly complex mixture of cells, enzymes, proteins, and inorganic substances. Plasma, which is the fluid portion of blood, is
Strategies to Improve Drug Tolerance in Nab Assays
Strategies to Improve Drug Tolerance in Nab Assays Steven J Swanson, PhD Senior Vice President, Research ImmunoCellular Therapeutics Ltd steven.swanson@imuc.com AAPS National Biotech Conference June 2015
MOLECULAR RECOGNITION
MOLECULAR RECOGNITION Bioanalytical Methods Classification 1. Biassay: molecular recognition, signal generation and detection in solution or on inert solid phase 2. Biosensor: molecular recognition system
Porcine IgM (Immunoglobulin M) ELISA Kit
Porcine IgM (Immunoglobulin M) ELISA Kit Catalogue No: EP0085 Size: 48T/96T Reactivity: Porcine Detection Range: 0.156-10ng/ml Sensitivity:
GSI Equine IL-10 ELISA Kit- Cell Lysate DataSheet
IL-10, also known as human cytokine synthesis inhibitory factor (CSIF), is an antiinflammatory cytokine that is produced by T cells, NK cells, mast cells and macrophages (1,2,3). It is capable of inhibiting
SAMPLE LITERATURE Please refer to included weblink for correct version.
REVISED & UPDATED Edvo-Kit #269 Introduction to ELISA Reactions Experiment Objective: This experiment introduces concepts and methodologies of enzyme-linked immunosorbent assays (ELISA). See page 3 for
Store samples to be assayed within 24 hours at 2-8 C. For long-term storage, aliquot and freeze samples at -20 C. Avoid repeated freeze-thaw cycles.
Human Retinol Binding Protein 4, RBP4 ELISA Kit Preparation Plate Washing Discard the solution in the plate without touching the side walls. Blot the plate onto paper towels or other absorbent material.
AssayMax Human Antithrombin III ELISA Kit
AssayMax Human Antithrombin III ELISA Kit Catalog # EA3302-1 Introduction The serine-protease-inhibitor antithrombin III (AT III), the most important natural inhibitor of thrombin activity, has been shown
BCH 462. Single Radial Immunodiffusion and Immuno-electrophoresis
BCH 462 Single Radial Immunodiffusion and Immuno-electrophoresis Immunoassays tests include: 1. Precipitation. 2. Agglutination. 3. Immunofluorescence. 4. Radioimmunoassay (RIA). 5. Enzyme-Linked Immuno
Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system
Clinical Chemistry 44:5 944 949 (1998) Enzymes and Protein Markers Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system Xavier Bossuyt, * Ann Bogaerts, Gilberte Schiettekatte,
Herpes Simplex 1 IgM (HSV1 IgM)
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
Human Rheumatoid Factor IgM ELISA Kit
Product Manual Human Rheumatoid Factor IgM ELISA Kit Catalog Number PRB- 5066 PRB- 5066 96 assays 5 x 96 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Rheumatoid arthritis
The Biotechnology Education Company. Quantitative ELISA. Storage: See Page 3 for specific storage instructions EXPERIMENT OBJECTIVE:
The Biotechnology Education Company Revised and Updated Quantitative ELISA Storage: See Page 3 for specific storage instructions EXPERIMENT OBJECTIVE: EDVO-Kit # 278 The objective of this experiment is
Assays for Immunogenicity: Are We There Yet?
Assays for Immunogenicity: Are We There Yet? Mark Wener, MD Department of Laboratory Medicine & Rheumatology Division Department of Medicine University of Washington Seattle, WA 98195 wener@uw.edu Goals:
Harmonization of red blood cell distribution width (RDW): an attainable target?
Original Article Page 1 of 5 Harmonization of red blood cell distribution width (RDW): an attainable target? Giuseppe Lippi 1, Silvia Pipitone 2, Emmanuel J. Favaloro 3,4 1 Section of Clinical Biochemistry,
chronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
Improving the Limit of Detection of Lateral Flow Assays using 3DNA Technology
Improving the Limit of Detection of Lateral Flow Assays using 3DNA Technology Introduction Lateral Flow (LF) and similar assays represent a unique growing class of Point of Care (POC) tests designed to
Mouse ICAM-1 / CD54 ELISA Pair Set
Mouse ICAM-1 / CD54 ELISA Pair Set Catalog Number : SEK50440 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized in the General
For In Vitro Diagnostic Use
SYNCHRON System(s) Chemistry Information Sheet Lactate Dehydrogenase REF 442660 For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by: Date Reviewed by: Date PRINCIPLE INTENDED USE reagent, when used in
Protein homology. Antigens & Antibodies I. Administrative issues:
Administrative issues: Recommended text: Goldsby/Kuby Immunology, 6th edition (Note that Innate Immunity is not adequately covered in the 5th edition.) Text book reading assignments are to supplement the
Practical Applications of Immunology (Chapter 18) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College Eastern Campus
Practical Applications of Immunology (Chapter 18) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College Eastern Campus Primary Source for figures and content: Tortora, G.J. Microbiology
FER PRINCIPLE SPECIMEN. REF (150 tests) ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE
IMMAGE Immunochemistry Systems Chemistry Information Sheet Copyright 2010 Beckman Coulter, Inc. Ferritin REF 447160 (150 tests) For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by: Date Reviewed by:
CHEMILUMINESCENCE ENZYME IMMUNOASSAY (CLIA) THYROID STIMULATING HORMONE (FERRITIN) Ferritin
DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and 116, Woodland hills CA 91367 USA Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com
CHAPTER 3 ANTIBODY STRUCTURE I
CHAPTER 3 ANTIBODY STRUCTURE I See APPENDIX: (3) OUCHTERLONY ANALYSIS; (6), EQUILIBRIUM DIALYSIS; (7) CROSS-REACTIVITY Electrophoretic separation of serum proteins identifies the GAMMA-GLOBULIN fraction
AssayMax TM. Human IgG ELISA Kit. Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO T (636) F (636)
AssayMax TM Human IgG ELISA Kit Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com For any questions regarding troubleshooting or performing
Human IL-10 ELISA MAX Set Deluxe
Human IL-10 ELISA MAX Set Deluxe Cat. No. 430604 (5 plates) 430605 (10 plates) 430606 (20 plates) ELISA Set for Accurate Cytokine Quantification from Cell Culture Supernatant, Serum, Plasma or Other Body
Human Fibrinogen Antigen Assay
Catalog # FIBKT 0 Human Fibrinogen Antigen Assay Strip well format. Reagents for up to 96 tests. For Research Use Only. INTENDED USE This human fibrinogen antigen assay is intended for the quantitative
Bovine IgG ELISA Kit
Bovine IgG ELISA Kit Cat. No. E11-118 Components Supplied Bovine IgG Pre-Coated 96-well Strip Plate, 1 each Bovine IgG Standard, 500 ng/vial, 2 each Bovine IgG Detection Antibody, 12 ml 20X Dilution Buffer
Human TGF-beta1 ELISA
K-ASSAY Human TGF-beta1 ELISA For the quantitative determination of TGF-beta1 in human cell culture supernates, serum, plasma (EDTA) and urine Cat. No. KT-1471 For Research Use Only. Not for diagnostic
CCQM P58.1: Metrology for Clinical Sciences. Diagnostic Formulation Meeting, 24 th Feb James Noble
CCQM P58.1: Metrology for Clinical Sciences Diagnostic Formulation Meeting, 24 th Feb James Noble Development of a Reference Immunoassay for ctni Cardiac Troponin I (ctni) is an important marker for the
Performance requirements for ctni measurement in clinical setting: need to standardize as well
5 th International CIRME Meeting STANDARDIZATION OF CARDIAC TROPONIN I: THE ONGOING IINTERNATIONAL EFFORTS NOVEMBER 30 th, 2011 Centre for Metrological Traceability in Laboratory Medicine (CIRME) Director:
Transferrin ELISA. For the quantitative determination of transferrin in human biological samples
Transferrin ELISA For the quantitative determination of transferrin in human biological samples Please see Appendix A for Reference Serum information. For Research Use Only. Not For Use In Diagnostic Procedures.
Target/drug interference considerations in immunogenicity assessment
Target/drug interference considerations in immunogenicity assessment Eric Wakshull, PhD Senior Scientist March 9, 2016 EMA Workshop on Immunogenicity Outline Page 2 Basic Immunogenicity screening assay
Mouse Fibrinogen ELISA
K-ASSAY Mouse Fibrinogen ELISA For the quantitative determination of fibrinogen in mouse biological samples Cat. No. KT-397 For research use only. 1 Rev. 9994397 K-ASSAY PRODUCT INFORMATION Mouse Fibrinogen
Mouse Factor XII Total ELISA Kit
Mouse Factor XII Total ELISA Kit Catalog No: IMFXIIKT-TOT Lot No: SAMPLE INTENDED USE This mouse coagulation Factor XII antigen assay is intended for the quantitative determination of total Factor XII
Human alpha-galactosidase A / GLA ELISA Pair Set
Human alpha-galactosidase A / GLA ELISA Pair Set Catalog Number : SEK12078 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized
Human IL10RB ELISA Pair Set ( CRFB4 )
Human IL10RB ELISA Pair Set ( CRFB4 ) Catalog Number : SEK10945 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized in the
The World Leader in SPR Technology. Jimmy Page, PhD, Biacore, Inc.
The World Leader in SPR Technology Jimmy Page, PhD, Biacore, Inc. Objectives of Biacore Experiments Yes/No Data» Is there binding?» Ligand Fishing Concentration Analysis: How MUCH? Active Concentration
WesternMAX Alkaline Phosphatase Chemiluminescent Detection Kits
WesternMAX Alkaline Phosphatase Chemiluminescent Detection Kits Code N221-KIT N220-KIT Description WesternMAX Chemiluminescent AP Kit, Anti-Mouse Includes: Alkaline Phosphatase (AP) Conjugated Anti-Mouse
B-cell Epitope Prediction and Cloning monoclonal ADAs
B-cell Epitope Prediction and Cloning monoclonal ADAs Stefan Ryser, CEO, Trellis Bioscience 3 rd International Symposium on Higher Order Structure of Protein Therapeutics Arlington, Virginia, February
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus
Accuracy of Serum IgM and IgA Monoclonal Protein Measurements by Densitometry
160 Annals of Clinical & Laboratory Science, vol. 33, no. 2, 2003 Accuracy of Serum IgM and IgA Monoclonal Protein Measurements by Densitometry C. Howard Tseng, 1 Chin-Yung Chang, 2 Kevin S. Liu, 3 and
Human Collagen Type III (COL3) ELISA
Human Collagen Type III (COL3) ELISA For the quantitative determination of human COL3 in serum, plasma, cell culture fluid and other biological fluids Cat. No. KT-61018 For Research Use Only. Not for use
Human Amyloid Beta Peptide 1-42 (Aβ1-42) ELISA Kit
Human Amyloid Beta Peptide 1-42 (Aβ1-42) ELISA Kit Catalog Number. For the quantitative determination of human amyloid beta peptide 1-42 (Aβ1-42) concentrations in serum, plasma, tissue homogenates, cerebrospinal
Protein A Assay. Cygnus Technologies, Inc. Revision #8-07. Immunoenzymetric Assay for the Measurement of Protein A Catalog # F400.
Protein A Assay Cygnus Technologies, Inc. Revision #8-07 Immunoenzymetric Assay for the Measurement of Protein A Catalog # F400 Intended Use This kit is intended for use in quantitating Protein A. The